Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor

University of Southern California

Overview

This pilot research trial studies the long term effects of tyrosine kinase inhibitor therapy on ovarian reserve and fertility in patients with chronic myeloid leukemia or gastrointestinal stromal tumor. Studying ovary imaging, ovarian reserve markers, and hormone levels from patients receiving tyrosine kinase inhibitor therapy may help doctors learn more about the effects of tyrosine kinase inhibitor therapy on ovarian function and fertility.

PRIMARY OBJECTIVES: I. To collect preliminary information to help design a study to look at longitudinal changes in markers of ovarian reserve and menstruation in premenopausal women undergoing tyrosine kinase inhibitors (TKI) therapy. SECONDARY OBJECTIVES: I. Evaluate ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo in vitro fertilization (IVF) for fertility preservation. OUTLINE: Patients undergo transvaginal ultrasound for antral follicles analysis and collection of serum for ovarian reserve markers and hormonal analysis before TKI therapy and at 12, 24, and 48 weeks.

Study Type

OBSERVATIONAL

Conditions

Chronic Myelogenous Leukemia, BCR-ABL1 Positive Gastrointestinal Stromal Tumor Premenopausal

Interventions

Cytology Specimen Collection ProcedureOTHER

Undergo collection of serum

Laboratory Biomarker AnalysisOTHER

Correlative studies

Questionnaire AdministrationOTHER

Ancillary studies

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 45 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Diagnosed with chronic myeloid leukemia (CML), gastrointestinal stromal tumor (GIST), non metastatic cancer where TKI is the first line agent * Premenopausal (has had menses at any time in the preceding 12 consecutive months) * Has not undergone a hysterectomy or bilateral oophorectomy * Willing to use non-hormonal (ie: barrier method or abstinence) as form of contraception during the one year of study Exclusion Criteria: * Patients who have had chemotherapy or radiotherapy in the past * Patients may not be receiving any other investigational agents * Patients must not be pregnant or nursing * Other medical conditions or treatments that affect hormonal levels (potentially confounding interpretation of results) * Patients with ongoing hormonal contraception or unwilling or unable to discontinue will not eligible

Locations (1)

USC / Norris Comprehensive Cancer Center

Los Angeles, California, United States

Outcomes

Primary Outcomes

Changes in markers of ovarian reserve in premenopausal women undergoing tyrosine kinase inhibitor therapy for cancer

Standard descriptive statistics and scatter plots will be used to summarize patterns by cohorts at each time point. Regression methods will be used to render data compatible with the assumption of the normal distribution. Analysis will be undertaken to obtain preliminary estimates of ovarian reserve over time and to elucidate whether TKI therapy produces a clinically meaningful change in ovarian reserve marker.

Time frame: Baseline to up to 1 year

Secondary Outcomes

Ovarian response to controlled ovarian hyperstimulation in patients who elect to undergo IVF for fertility preservation

The results of their stimulation protocol will be recorded.

Time frame: Up to 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.